TELA Bio TELA
TELA Bio Bio reported a net loss of $9.3 million
TELA Bio (TELA) filed a 10-Q with the SEC on Nov 10, 2026, 4:16 pm ET. Source: the filing on SEC EDGAR.
- Form
- 10-Q
- Filed
- Importance
- Notable
- Accession
- 0001104659-26-125190
- Revenue: $18.96 million for the three months ended Sep 30, 2026
- Net loss: $9.3 million for the three months ended Sep 30, 2026
- Diluted EPS: -$0.16 for the three months ended Sep 30, 2026
- Cash and equivalents: $22.66 million at Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
Going-concern warning repeated
“These conditions and events raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued.”
Also in the prior 10-Q (filed Aug 11, 2026). Prior report Prior on EDGAR
Quoted from the filing.
What changed since last quarter
No new risk factors or legal mentions.
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Revenue | $18.96M | $19.29M | −1.7% |
| Operating income and margin | −$7.29M · -38.5% | −$9.28M · -48.1% | +22%, margin +9.6 pts |
| Net income | −$9.3M | −$11.26M | +17% |
| Operating cash flow | −$8.69M | −$9.38M | +7.3% |
| Cash | $22.66M | $30.42M | −26% |